The dual regulatory approvals (FDA and DKMA) de-risk the Phase 2b program and validate Enlivex's multinational strategy. Traders should monitor initiation of patient enrollment and interim data readouts, which could serve as catalysts for valuation re-rating in this high-unmet-need indication.
Price Chart
Executive Summary
Enlivex announced regulatory approval from Denmark's DKMA to initiate its Phase 2b trial of Allocetra for moderate-to-severe knee osteoarthritis, following recent FDA clearance in the U.S. The global trial will enroll patients in the U.S., Denmark, and Poland in a placebo-controlled study assessing pain, function, and quality of life.
Key Facts
- Enlivex received Clinical Trial Application (CTA) approval from Denmark's DKMA for its Phase 2b trial of Allocetra in knee osteoarthritis.
- This follows recent FDA clearance in the U.S., enabling a global, multicenter, randomized, double-blind, placebo-controlled trial.
- The trial will evaluate intra-articular injections of Allocetra on pain, physical function, and quality of life in patients with moderate-to-severe age-related knee OA.
- Patient enrollment is expected to begin soon across sites in the U.S., Denmark, and Poland.
Financial Impact
No direct financial impact disclosed; advancement in clinical development increases pipeline value.
Risk Factors
- Clinical trial may fail to meet efficacy or safety endpoints in later stages.
- Company's dual focus on biotech and crypto-based prediction markets may distract investors or raise governance concerns.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 press releases from GlobeNewswire.
| Document | Accession Number |
|---|---|
| 6-K Filing (ENLV) — Batch item 1 | 0001213900-26-045892 |
| Document: ea028706001-6k_enlivex.htm | 0001213900-26-045892 |
| Document: 0001213900-26-045892-index-headers.html | press-3277942 |
| Document: 0001213900-26-045892-index.html | press-3277942 |
| Document: 0001213900-26-045892.txt | press-3277942 |
| PRESS-RELEASE Data (Synthetic) | press-3277942 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $0.1734 | awaiting T+5 | — | $2.70 (−1457.09%) |
Oct 22, 2026 5d ago | 6-K | $0.1734 | awaiting T+5 | — | $2.70 (+1457.09%) |
Oct 22, 2026 5d ago | Press Release | $0.1734 | awaiting T+5 | — | $2.70 (+1457.09%) |
Oct 19, 2026 8d ago | 6-K | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.70 (−1204.35%) |
Oct 19, 2026 8d ago | Press Release | $0.2070 $0.1704 | ▲ +17.68% | ▲ +17.54% | $2.70 (−1204.35%) |
Sep 25, 2026 4w ago | 6-K | $0.5140 $0.3620 | ▼ −29.57% | ▼ −30.78% | $2.70 (+425.29%) |
Sep 22, 2026 5w ago | 6-K | $0.6464 $0.4801 | ▼ −25.73% | ▼ −24.54% | $2.70 (+317.70%) |
Aug 14, 2026 10w ago | EFFECT | $1.58 $1.47 | ▼ −6.96% | ▼ −5.59% | $2.70 (+70.89%) |
Jul 30, 2026 12w ago | 6-K | $1.95 $1.98 | ▲ +1.54% | ▼ −2.08% | $2.70 (+38.46%) |
Jul 29, 2026 12w ago | 6-K | $2.25 $2.18 | ▼ −3.11% | ▼ −8.64% | $2.70 (+20.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers